LeszynskyHE, ZondekGW, ZondekH. Refractoriness to thyroid hormone in hypothyroid patients. Acta Endocrinol (Copenh), 1956; 23(2):145–150; doi: 10.1530/acta.0.0230145.
2.
CentanniM, BenvengaS, SachmechiI. Diagnosis and management of treatment-refractory hypothyroidism: An expert consensus report. J Endocrinol Invest, 2017; 40(12):1289–1301; doi: 10.1007/s40618-017-0706-y.
3.
Quiroz-AldaveJE, Conceptionción-ZavaletaMJ, Durand-VásquezMDC, et al.Refractory hypothyroidism: Unraveling the complexities of diagnosis and management. Endocr Pract, 2023; 29(12):1007–1016; doi: 10.1016/j.eprac.2023.09.003.
4.
LawLS-C, KuuNWX, LeongMHT, et al.Subcutaneous levothyroxine administration in treatment of refractory primary hypothyroidism: A case report. Thyroid. Epub, 2025 Dec 17; doi: 10.1177/10507256251409071.
PerezCL, et al.Serum thyrotropin levels following levothyroxine administration at breakfast. Thyroid, 2013; 23(7):779–784; doi: 10.1089/thy.2012.0435.
7.
GonzalesKM, StanMN, MorrisJC3rd, et al.The levothyroxine absorption test: A four-year experience (2015-2018) at The Mayo Clinic. Thyroid, 2019; 29(12):1734–1742; doi: 10.1089/thy.2019.0256.
8.
BarbarB, HossenS, QuintonR, et al.Levothyroxine absorption test: A therapeutic strategy for improving medication adherence. Clin Endocrinol (Oxf), 2023; 98(5):741–742; doi: 10.1111/cen.14902.
9.
JayakumariC, NairA, KhadarJP, et al.Efficacy and safety of once-weekly thyroxine for thyroxine-resistant hypothyroidism. J Endocr Soc, 2019; 3(12): 2184–2193; doi: 10.1210/js.2019-00212.
10.
FitchR, MouldDR, ConoscentiV, et al.Phase 1 study evaluating the pharmacokinetics, dose proportionality, bioavailability, and tolerability of subcutaneous levothyroxine sodium (XP-8121). Clin Transl Sci, 2025; 18(5): e70244; doi: 10.1111/cts.70244.
